Vimarsana
Biggest News Aggregation in the World

Page 12 - Patrick Wingrove News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Wingrove Today - Breaking & Trending Today

US Employers Hire Virtual Providers as Weight-loss Drug Gatekeepers - Vimarsana News

US Employers Hire Virtual Providers as Weight-loss Drug Gatekeepers

U.S. employers facing surging costs from paying for Novo Nordisk’s Wegovy and similar obesity drugs are hiring virtual healthcare providers like Teladoc to implement...

US Sets Policy to Seize Patents If Drug Price Deemed Too High - Vimarsana News

US Sets Policy to Seize Patents If Drug Price Deemed Too High

The Biden Administration has announced it is setting new policy that will allow it to seize patents for medicines developed with government funding if it believes their prices are too high.

US sets policy to seize government-funded drug patents if price deemed too high - Vimarsana News

US sets policy to seize government-funded drug patents if price deemed too high

By Patrick Wingrove (Reuters) - The Biden Administration on Thursday announced it is setting new policy that will allow it to seize patents for medici...

Source: kelo.com
US sets policy to seize government-funded drug patents if price deemed too high - Vimarsana News

US sets policy to seize government-funded drug patents if price deemed too high

By Patrick Wingrove (Reuters) -The Biden Administration on Thursday announced it is setting new policy that will allow it to seize patents for medicines ...

Johnson & Johnson forecasts as much as 6% sales growth in 2024 - Vimarsana News

Johnson & Johnson forecasts as much as 6% sales growth in 2024

The company has narrowed its focus on its drugs and medical devices business since it hived off its consumer health unit earlier this year. "We think we're very well positioned, even in spite of what will be the beginning of some biosimilar entrants to Stelara outside the US in mid to second half of 2024," Chief Financial Officer Joseph Wolk told Reuters. J&J, which plans to launch at least 20 new therapies by 2030, said over 10 of its products had the potential to generate more than $5 billion in peak year sales - including newer cancer treatments Talvey and Tecvayli.

Source: yahoo.com